Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
Volume 0.52M
Average 0.86M
NAGE Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Niagen Bioscience IncNASDAQ: NAGE
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $16.92M rose 27.2% year over year, behind the +34.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 5.4% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.
Context
- Selling, general & admin amounted to 48.3% of revenue in FY2025, up 0.3 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $78.82M (+26.0%) for the fiscal year ending Dec 2026, a slowdown from the +30.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $16.92M-5.4% QoQ
- Last fiscal yearDec 2025
- $62.56M+30.8% YoY
- LTMMar 2026
- $66.18M+34.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 62.56M USD
- Year-over-year change
- +30.8%
- 4-year CAGR
- -0.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.56M | +30.8% |
| FY2024 | 2024-12-31 | 47.84M | -7.0% |
| FY2023 | 2023-12-31 | 51.42M | -9.1% |
| FY2022 | 2022-12-31 | 56.6M | -12.6% |
| FY2021 | 2021-12-31 | 64.73M | — |
Selling, General & Admin vs competitors
How NAGE compares with its peers on the latest reported figures
- NAGE's LTM Mar 2026 selling, general & admin of $66.18M is the 6th highest of the 10 companies compared; the peer median is $78.85M.
- Its year-over-year change of +34.9% is the 3rd highest of 9, against a peer median of +17.9%.
- Selling, general & admin amounts to 50.7% of revenue for NAGE, versus a peer median of 94.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $198.25M | — | — | 171.0% | |
| LTM Mar 2026 | $118.84M | +5.8% | +1.0% | 39.6% | |
| LTM Mar 2026 | $113.07M | +41.5% | -8.1% | 48.7% | |
| LTM Mar 2026 | $83.82M | +6.5% | -1.0% | 95.4% | |
| LTM Mar 2026 | $78.85M | +22.3% | +72.8% | 64.5% | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | $66.18M | +34.9% | +3.4% | 50.7% |
| LTM Mar 2026 | $54.46M | -19.1% | +6.0% | 94.0% | |
| LTM Mar 2026 | $46.5M | +13.6% | +19.4% | 140.1% | |
| LTM Mar 2026 | $25.39M | +44.8% | -5.3% | — | |
| LTM Mar 2026 | $10.49M | +24.0% | +4.5% | — | |
| Peer median (excluding NAGE) | $78.85M | +17.9% | +2.8% | 94.0% | |
Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 67.45M | 72.05M | 83.57M | 99.6M | 129.42M |
| Cost of Revenue | 25.96M | 29.25M | 32.79M | 38.01M | 46.23M |
| Gross Profit | 41.49M | 42.8M | 50.78M | 61.59M | 83.19M |
| Gross Margin | 61.5% | 59.4% | 60.8% | 61.8% | 64.3% |
| Research & Development | 3.83M | 4.83M | 4.96M | 6.02M | 6.33M |
| Selling, General & Admin | 64.73M | 56.6M | 51.42M | 47.84M | 62.56M |
| Operating Expenses | 68.56M | 61.43M | 56.38M | 53.86M | 68.89M |
| Depreciation & Amortization | 1.63M | 1.88M | 1.71M | 1.48M | 1.45M |
| EBITDA | (25.45M) | (14.66M) | (3.23M) | 10.34M | 19.64M |
| EBITDA Margin | -37.7% | -20.3% | -3.9% | 10.4% | 15.2% |
| Operating Income | (27.07M) | (18.63M) | (5.6M) | 7.73M | 14.3M |
| Operating Margin | -40.1% | -25.9% | -6.7% | 7.8% | 11.0% |
| Interest Income | 0 | 3K | 661K | 1.13M | 2.13M |
| Interest Expense | 55K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (55K) | 2.09M | 661K | 1.13M | 3.9M |
| Income Before Tax | (27.13M) | (16.54M) | (4.94M) | 8.86M | 18.19M |
| Pre-Tax Margin | -40.2% | -23.0% | -5.9% | 8.9% | 14.1% |
| Income Tax Expense | 0 | 0 | 0 | 305K | 810K |
| Net Income | (27.13M) | (16.54M) | (4.94M) | 8.55M | 17.38M |
| Net Margin | -40.2% | -23.0% | -5.9% | 8.6% | 13.4% |
| EPS (Basic) | (0.40) | (0.24) | (0.07) | 0.10 | 0.22 |
| EPS (Diluted) | (0.40) | (0.24) | (0.07) | 0.11 | 0.20 |
| Weighted Avg Shares | 67.19M | 68.92M | 70.54M | 85.42M | 79.18M |
| Weighted Avg Shares (Diluted) | 67.19M | 69.73M | 74.99M | 79.72M | 85.44M |
Niagen Bioscience Inc
NASDAQ:NAGE
Intrinsic Alpha fair value
Locked
Current Price
$1.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.